VYDURA

This brand name is authorized in Austria, Estonia, Spain, France, Croatia, Italy, Lithuania, Romania

Active ingredients

The drug VYDURA contains one active pharmaceutical ingredient (API):

1 Rimegepant UNII 1383NM3Q0H - RIMEGEPANT SULFATE

Rimegepant selectively binds with high affinity to the human calcitonin gene-related peptide (CGRP) receptor and antagonizes CGRP receptor function. The relationship between pharmacodynamic activity and the mechanism(s) by which rimegepant exerts its clinical effects is unknown. Read about Rimegepant

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
VYDURA Oral lyophilisate	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N02CD06		N Nervous system → N02 Analgesics → N02C Antimigraine preparations → N02CD Calcitonin gene-related peptide (CGRP) antagonists
Discover more medicines within N02CD06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1882144, 1882155
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1221645002
Country: FR	Base de données publique des médicaments	Identifier(s): 65899221
Country: IT	Agenzia del Farmaco	Identifier(s): 050080011, 050080023, 050080035
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1094639, 1094640
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W68828001, W68828002